Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential

(2021) Vanaja Konduri et al.   Frontiers in Immunology

Recruiting T cells in cancer immunotherapy

(2021) Kathryn E. Yost et al.   SCIENCE

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

(2021) Romain Banchereau et al.   Journal for ImmunoTherapy of Cancer

Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthy

(2021) Vivien Béziat et al.   CELL

CD96 functions as a co‐stimulatory receptor to enhance CD8 + T cell activation and effector responses

(2020) Eugene Y. Chiang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Peripheral T cell expansion predicts tumour infiltration and clinical response

(2020) Thomas D. Wu et al.   NATURE

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2

(2020) Xiaozheng Xu et al.   JOURNAL OF CELL BIOLOGY

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

(2020) Delvys Rodriguez-Abreu et al.   JOURNAL OF CLINICAL ONCOLOGY

CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy

(2020) Hyung-seung Jin et al.   Cancer Immunology Research

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

(2020) Marianne Weulersse et al.   IMMUNITY

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

(2020) Matthias Braun et al.   IMMUNITY

A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects

(2020) Fang Yang et al.   JOURNAL OF IMMUNOLOGY

TIGIT in cancer immunotherapy

(2020) Joe-Marc Chauvin et al.   Journal for ImmunoTherapy of Cancer

Resident Memory T Cells and Their Effect on Cancer

(2020) Daniel J. Craig et al.   Vaccines

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

(2020) Camille-Charlotte Balança et al.   JCI Insight

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

Comprehensive Integration of Single-Cell Data

(2019) Tim Stuart et al.   CELL

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Tissue-Resident Memory T Cells in Cancer Immunosurveillance

(2019) Simone L. Park et al.   TRENDS IN IMMUNOLOGY

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

(2019) Shuang Qin et al.   Molecular Cancer

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

(2019) Caroline S. Jansen et al.   NATURE

CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions

(2018) Masao Hashimoto et al.   Annual Review of Medicine

Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens

(2018) Jeremy D. Waight et al.   CANCER CELL

Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity

(2018) Karen O. Dixon et al.   JOURNAL OF IMMUNOLOGY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

Tissue-resident memory T cells at the center of immunity to solid tumors

(2018) Derk Amsen et al.   NATURE IMMUNOLOGY

Fine-tuning of substrate preferences of the Src-family kinase Lck revealed through a high-throughput specificity screen

(2018) Neel H Shah et al.   eLife

High-dimensional single cell analysis identifies stem-like cytotoxic CD8+T cells infiltrating human tumors

(2018) Jolanda Brummelman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

CD226 regulates natural killer cell antitumor responses via phosphorylation-mediated inactivation of transcription factor FOXO1

(2018) Xiangnan Du et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

(2017) Solange Peters et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

(2017) Nicholas A. Manieri et al.   TRENDS IN IMMUNOLOGY

Reversing T-cell Dysfunction and Exhaustion in Cancer

(2016) H. M. Zarour   CLINICAL CANCER RESEARCH

T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections

(2016) Daniel T. Utzschneider et al.   IMMUNITY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

TIGIT predominantly regulates the immune response via regulatory T cells

(2015) Sema Kurtulus et al.   JOURNAL OF CLINICAL INVESTIGATION

The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function

(2014) Robert J. Johnston et al.   CANCER CELL

Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses

(2014) Nicole Joller et al.   IMMUNITY

T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling

(2014) Man Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

In vitro membrane reconstitution of the T-cell receptor proximal signaling network

(2014) Enfu Hui et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR

(2013) Noa Stanietsky et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

(2012) S Liu et al.   CELL DEATH AND DIFFERENTIATION

The TIGIT/CD226 Axis Regulates Human T Cell Function

(2012) E. Lozano et al.   JOURNAL OF IMMUNOLOGY

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering

(2012) K. F. Stengel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

Identification of Endothelial Cell Junctional Proteins and Lymphocyte Receptors Involved in Transendothelial Migration of Human Effector Memory CD4+ T Cells

(2010) T. D. Manes et al.   JOURNAL OF IMMUNOLOGY

DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors

(2008) Susan Gilfillan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY